



## Vimpat® (lacosamide) – Expanded indication

- On October 14, 2021, the [FDA approved](#) UCB's [Vimpat \(lacosamide\)](#), for the treatment of partial-onset seizures in patients 1 month of age and older.
  - Vimpat was previously approved for this indication in patients 4 years of age and older.
- Vimpat is also approved as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Vimpat is a Schedule V controlled substance.
- The use of Vimpat in pediatric patients 1 month to less than 17 years of age is supported by evidence from adequate and well-controlled studies of Vimpat in adults with partial-onset seizures, pharmacokinetic data from adult and pediatric patients, and safety data in 847 pediatric patients 1 month to less than 17 years of age.
- The recommended dosage of Vimpat for monotherapy and adjunctive therapy for partial-onset seizures in patients 1 month of age and older is dependent on body weight. Dosage should be increased based on clinical response and tolerability, no more frequently than once per week.
- Refer to the Vimpat drug label for complete dosing information for partial-onset seizures and for dosing in primary generalized tonic-clonic seizures.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.